Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® ...
On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for immune thrombocytopenia, received U.S. FDA breakthrough therapy designation and orphan drug ...
The Warm Autoimmune Hemolytic Anemia Waiha Treatment Market plays a crucial role in modern hematology by enabling more precise and effective treatment options. It supports the development of novel ...
The Silent Thief of Vitality Dr Randhir Singh dr.randhirlo@gmail.com If your dog appears lethargic, skips meals, or lacks energy, it may not be temporary. Anemia, a condition where the dog lacks ...
Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...
Sanofi wins FDA Breakthrough Therapy and Japan Orphan designations for Wayrilz in wAIHA, backed by LUMINA data and a late-stage study.
The pathophysiology of warm autoimmune hemolytic anemia (AIHA) is based on more than isolated red blood cell (RBC) destruction. Several complex biological mechanisms and signaling disruptions within ...
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic ...
Like many autoimmune conditions, researchers do not know the exact trigger causing these autoantibodies to target healthy RBCs. These cases are classified as primary or idiopathic warm AIHA. In other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results